- Home
- WLKP vs OCS Comparison
WLKP vs OCS Comparison
Compare WLKP & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLKP
- OCS
- Stock Information
- Founded
- WLKP 2014
- OCS 2003
- Country
- WLKP United States
- OCS Switzerland
- Employees
- WLKP N/A
- OCS N/A
- Industry
- WLKP Major Chemicals
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- WLKP Industrials
- OCS Health Care
- Exchange
- WLKP Nasdaq
- OCS Nasdaq
- Market Cap
- WLKP 817.5M
- OCS 904.3M
- IPO Year
- WLKP 2014
- OCS N/A
- Fundamental
- Price
- WLKP $23.14
- OCS $18.30
- Analyst Decision
- WLKP
- OCS Strong Buy
- Analyst Count
- WLKP 0
- OCS 4
- Target Price
- WLKP N/A
- OCS $29.50
- AVG Volume (30 Days)
- WLKP 22.8K
- OCS 38.2K
- Earning Date
- WLKP 04-30-2025
- OCS 03-11-2025
- Dividend Yield
- WLKP 8.10%
- OCS N/A
- EPS Growth
- WLKP 14.91
- OCS N/A
- EPS
- WLKP 1.77
- OCS N/A
- Revenue
- WLKP $1,135,896,000.00
- OCS $757,024.00
- Revenue This Year
- WLKP $8.90
- OCS $927.26
- Revenue Next Year
- WLKP $6.87
- OCS $292.79
- P/E Ratio
- WLKP $13.12
- OCS N/A
- Revenue Growth
- WLKP N/A
- OCS N/A
- 52 Week Low
- WLKP $21.19
- OCS $10.61
- 52 Week High
- WLKP $25.04
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- WLKP 41.11
- OCS 34.97
- Support Level
- WLKP $23.00
- OCS $18.30
- Resistance Level
- WLKP $23.45
- OCS $19.98
- Average True Range (ATR)
- WLKP 0.30
- OCS 0.65
- MACD
- WLKP -0.01
- OCS -0.00
- Stochastic Oscillator
- WLKP 21.23
- OCS 6.59
About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.